542650 Panoramica delle azioni Metropolis Healthcare Limited fornisce servizi diagnostici in India e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Non sono stati rilevati rischi per 542650 dai nostri controlli di rischio.
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Metropolis Healthcare Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Metropolis Healthcare Prezzi storici delle azioni Prezzo attuale dell'azione ₹1,842.95 Massimo di 52 settimane ₹2,306.85 Minimo di 52 settimane ₹1,555.55 Beta 0.37 Variazione di 1 mese -8.90% Variazione a 3 mesi -12.87% Variazione di 1 anno 12.33% Variazione a 3 anni -23.84% Variazione a 5 anni 3.98% Variazione dall'IPO 92.06%
Notizie e aggiornamenti recenti
Third quarter 2025 earnings: EPS misses analyst expectations Feb 05 Metropolis Healthcare Limited Announces Resignation of Balakrishnan Janardhanan as Chief Business Officer (South-East), Effective March 31, 2025 Metropolis Healthcare Limited (NSEI:METROPOLIS) agreed to acquire Core Diagnostics Private Limited from Core Diagnostics (Mauritius) Private Limited for INR 2.46 billion. Dec 10
Metropolis Healthcare Limited Announces Management Changes Nov 28
Second quarter 2025 earnings: EPS misses analyst expectations Nov 09
Metropolis Healthcare Limited Appoints Aditya Shinde as Interim Chief Financial Officer, Effective November 11, 2024 Nov 08 Vedi altri aggiornamenti
Third quarter 2025 earnings: EPS misses analyst expectations Feb 05 Metropolis Healthcare Limited Announces Resignation of Balakrishnan Janardhanan as Chief Business Officer (South-East), Effective March 31, 2025 Metropolis Healthcare Limited (NSEI:METROPOLIS) agreed to acquire Core Diagnostics Private Limited from Core Diagnostics (Mauritius) Private Limited for INR 2.46 billion. Dec 10
Metropolis Healthcare Limited Announces Management Changes Nov 28
Second quarter 2025 earnings: EPS misses analyst expectations Nov 09
Metropolis Healthcare Limited Appoints Aditya Shinde as Interim Chief Financial Officer, Effective November 11, 2024 Nov 08
Metropolis Healthcare Limited to Report Q2, 2025 Results on Nov 08, 2024 Oct 31 Metropolis Healthcare Limited Announces Resignation of Rakesh Agarwal as Chief Financial Officer, Effective November 10, 2024 Oct 12
Metropolis Healthcare Limited Appoints Pinakin Shah as Chief Information Officer Sep 07 Metropolis Healthcare Limited Announces Changes in Board
Founder & Chairman Emeritus recently sold ₹136m worth of stock Aug 22
Metropolis Healthcare Limited to Report Q1, 2025 Results on Aug 10, 2024 Aug 05
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 02 Metropolis Healthcare Limited, Annual General Meeting, Aug 21, 2024
Metropolis Healthcare Limited, Annual General Meeting, Aug 21, 2024 Jul 29
Founder & Chairman Emeritus recently sold ₹51m worth of stock Jun 13
Price target increased by 7.4% to ₹1,861 Jun 08
Metropolis Healthcare Limited Appoints Sushil Shah as Chairman Emeritus, Effective May 22, 2024 May 23
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 22
Metropolis Healthcare Limited to Report Q4, 2024 Results on May 21, 2024 May 16
Founder & Executive Chairman recently sold ₹62m worth of stock Apr 03
Third quarter 2024 earnings: EPS misses analyst expectations Feb 05
Metropolis Healthcare Limited Announces Management Changes Feb 02
Metropolis Healthcare Limited to Report Q3, 2024 Results on Feb 02, 2024 Jan 27
Upcoming dividend of ₹4.00 per share at 0.5% yield Nov 10
Price target increased by 7.4% to ₹1,528 Nov 07
Second quarter 2024 earnings: EPS misses analyst expectations Nov 07
Metropolis Healthcare Limited to Report Q2, 2024 Results on Nov 04, 2023 Oct 29
Metropolis Healthcare Limited Announces the Cessation of Milind Sarwate as an Independent Director, Chairman/Member of Audit Committee, Risk Management Committee and Corporate Social Responsibility Committee, Effective September 06, 2023 Sep 07
Metropolis Healthcare Limited to Report Q1, 2024 Results on Aug 02, 2023 Jul 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Jul 26
Metropolis Healthcare Limited, Annual General Meeting, Aug 17, 2023 Jul 24
Metropolis Healthcare Limited Appoints Neha Shah as Interim Company Secretary Jun 22
Insufficient new directors Jun 01
Price target decreased by 7.5% to ₹1,397 May 19
Full year 2023 earnings: EPS and revenues miss analyst expectations May 17
Metropolis Healthcare Limited to Report Q4, 2023 Results on May 16, 2023 May 11
Upcoming dividend of ₹8.00 per share at 0.6% yield Feb 16
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Feb 12
Metropolis Healthcare Limited Declares Interim Dividend for the Financial Year 2022-23 Feb 11
Metropolis Healthcare Limited to Report Q3, 2023 Results on Feb 10, 2023 Feb 04
Second quarter 2023 earnings: EPS misses analyst expectations Nov 10
Metropolis Healthcare Limited to Report Q2, 2023 Results on Nov 08, 2022 Nov 02
Metropolis Healthcare Limited Announces Resignation of Vijender Singh as Chief Execution Officer Aug 19
Metropolis Healthcare Limited Proposes to Confirm the Payment of Interim Dividend for the Financial Year Ended March 31, 2022 Aug 18
Price target decreased to ₹1,746 Aug 14
Metropolis Healthcare Limited to Report Q1, 2023 Results on Aug 10, 2022 Aug 04
Metropolis Healthcare Limited Announces Resignation of Chief Executive Officer, Effective November 30, 2022 Jul 30
Full year 2022 earnings: EPS and revenues miss analyst expectations Jul 28
Metropolis Healthcare Limited, Annual General Meeting, Aug 17, 2022 Jul 22
Metropolis Healthcare Limited to Report Q4, 2022 Final Results on Jul 18, 2022 Jul 13
GSK Velu Reportedly in Talks with Investors, PEs & Banking Firms to Buy Back Metropolis Healthcare Jun 15 Metropolis Confirms Promoters Have No Intention to Exit the Business
Adani, Apollo Reportedly Explore Bids for Majority Stake in Metropolis Jun 07
Price target decreased to ₹2,461 May 26
Full year 2022 earnings: EPS and revenues miss analyst expectations May 26
Amazon, Flipkart Reportedly in Talks to Buy Stake in Metropolis Healthcare May 21
Metropolis Healthcare Limited to Report Q4, 2022 Results on May 24, 2022 May 17
Investor sentiment improved over the past week Apr 05
Founder & Executive Chairman recently bought ₹100m worth of stock Feb 23
Investor sentiment deteriorated over the past week Feb 18
Upcoming dividend of ₹8.00 per share Feb 14
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Feb 13
Metropolis Healthcare Limited Declares Payment of an Interim Dividend Feb 12
Metropolis Healthcare Limited to Report Q3, 2022 Results on Feb 11, 2022 Feb 04
Investor sentiment deteriorated over the past week Jan 24
Insider recently sold ₹820k worth of stock Jan 01
Price target increased to ₹2,998 Dec 01
Founder & Executive Chairman recently sold ₹1.3b worth of stock Nov 18
Second quarter 2022 earnings released: EPS ₹11.39 (vs ₹11.88 in 2Q 2021) Nov 11
High number of new directors Oct 31
Key Executive recently sold ₹4.8m worth of stock Sep 14
Insider recently sold ₹1.7m worth of stock Sep 04
Price target increased to ₹2,789 Aug 09
Full year 2021 earnings released: EPS ₹35.97 (vs ₹25.36 in FY 2020) Jul 20
Suburban Diagnostics Reportedly in Sale Talks with Dr. Lal PathLabs, Metropolis, Pharmeasy, Others Jun 18
Company Secretary & Compliance Officer Poonam Tanwani has left the company Jun 04
Insider recently sold ₹7.8m worth of stock Jun 03
Price target increased to ₹2,466 May 31
Full year 2021 earnings released: EPS ₹35.97 (vs ₹25.36 in FY 2020) May 30
Chief Executive Officer recently sold ₹5.2m worth of stock Mar 31
Insider recently sold ₹999k worth of stock Mar 23
Chief Executive Officer recently sold ₹109m worth of stock Feb 24
Third quarter 2021 earnings released: EPS ₹11.50 (vs ₹8.38 in 3Q 2020) Feb 12
Revenue and earnings miss expectations Feb 12
Metropolis Healthcare Limited Revises Constitution of the Nomination and Remuneration Committee, with Effect from February 10, 2021 Feb 11
Metropolis Healthcare Limited to Report Q3, 2021 Results on Feb 10, 2021 Feb 05
Price target raised to ₹2,193 Jan 19
Metropolis Healthcare Limited (NSEI:METROPOLIS) agreed to acquire Dr. Ganesan's Hitech Diagnostic Centre Private Limited from Ganesan Subramanian, Manimegalai Ganesan and Malini Parasuraman for INR 6.2 billion. Jan 19
Insider recently sold ₹2.7m worth of stock Jan 08
Insider recently sold ₹2.0m worth of stock Dec 12
Insider recently sold ₹2.0m worth of stock Nov 21
New 90-day high: ₹2,040 Nov 18
Price target raised to ₹2,034 Nov 14 Rendimenti per gli azionisti 542650 IN Healthcare IN Mercato 7D 2.6% 2.7% -0.1% 1Y 12.3% 19.2% 5.7%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 542650 ha avuto una performance inferiore rispetto al Indian Healthcare che ha registrato un rendimento 19.2 % nell'ultimo anno.
Rendimento vs Mercato: 542650 ha superato il mercato Indian che ha restituito 5.7 % nell'ultimo anno.
Volatilità dei prezzi Is 542650's price volatile compared to industry and market? 542650 volatility 542650 Average Weekly Movement 4.2% Healthcare Industry Average Movement 5.7% Market Average Movement 6.3% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.3%
Prezzo delle azioni stabile: 542650 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di 542650 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Metropolis Healthcare Limited fornisce servizi diagnostici in India e a livello internazionale. L'azienda offre analisi cliniche di laboratorio e servizi di profilazione. Fornisce inoltre servizi diagnostici per l'oncologia, la neurologia, la ginecologia e la nefrologia, oltre a vari pacchetti di check-up sanitari per uomini, donne, anziani, giovani e aziende.
Mostra di più Metropolis Healthcare Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Metropolis Healthcare con la sua capitalizzazione di mercato? 542650 statistiche fondamentali Capitalizzazione di mercato ₹94.30b Guadagni(TTM ) ₹1.52b Ricavi(TTM ) ₹13.17b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 542650 Conto economico (TTM ) Ricavi ₹13.17b Costo del fatturato ₹2.92b Profitto lordo ₹10.25b Altre spese ₹8.73b Guadagni ₹1.52b
Ultimi guadagni dichiarati
Dec 31, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 29.69 Margine lordo 77.86% Margine di profitto netto 11.56% Rapporto debito/patrimonio netto 16.0%
Come si è comportato 542650 nel lungo periodo?
Vedi performance storica e confronto Dividendi
0.2% Rendimento attuale del dividendo
0% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/07 06:32 Prezzo dell'azione a fine giornata 2025/02/07 00:00 Guadagni 2024/12/31 Guadagni annuali 2024/03/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche Metropolis Healthcare Limited è coperta da 35 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Nitin Bhasin Ambit Capital Prashant Nair Ambit Capital null null Antique Stockbroking Ltd.
Mostra 32 altri analisti 
